Premium
Impact of family history of colorectal cancer on age‐specific prevalence of colorectal neoplasia
Author(s) -
Park Chan Hyuk,
Kim Nam Hee,
Park Jung Ho,
Park Dong Il,
Sohn Chong Il,
Jung Yoon Suk
Publication year - 2019
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.14553
Subject(s) - family history , medicine , colorectal cancer , odds ratio , colonoscopy , confidence interval , risk factor , colorectal adenoma , cancer
Background and Aim There are no established guidelines on screening strategies for persons with a family history of colorectal cancer (CRC) in Korea. We aimed to evaluate the age‐specific risk of colorectal neoplasia according to family history of CRC. Methods Participants who underwent screening colonoscopy were included. Age‐specific prevalence of non‐advanced adenoma (NAA) and advanced colorectal neoplasia (ACRN) was calculated according to family history of CRC. Results Among 35 997 participants, 1339 (3.7%) had a family history of CRC in first‐degree relatives. A family history of CRC was an independent risk factor for NAA (adjusted odds ratio [AOR] 1.33, 95% confidence interval [CI] 1.16–1.52). In the subgroup analysis by age, family history of CRC was a risk factor for NAA in the 50–59 and ≥ 60 years groups (AOR [95% CI]: 1.42 [1.04–1.91] and 2.33 [1.34–4.09], respectively), but not in the 30–39 and 40–49 years groups. In the curve of age‐specific prevalence of NAA, the gap of the prevalence between the family history and non‐family history groups began to widen after the mid‐50s. In cases of ACRN, a family history of CRC was not a risk factor in the entire age group (AOR 1.16, 95% CI 0.75–1.70). In the curve of age‐specific prevalence of ACRN, however, the gap of the prevalence between the family history and non‐family history groups began to widen after the early 60s. Conclusion Although a family history of CRC is a risk factor for NAA, it may affect NAA development from the mid‐50s and ACRN development from the early 60s.